Aarti Industries Ltd — May 2025 Quarterly Analysis

1. VERDICT & BUSINESS QUALITY SNAPSHOT

Result: Inline **One-line:** The thesis remains in a "patience and execution" phase: management successfully hit its revised FY25 EBITDA floor through volume-led growth (+17%), but structural pricing headwinds from China prevent the margin recovery needed to accelerate deleveraging.

Dimension	This Quarter	Signal / Evidence	Sentiment
Beat/Miss vs Guidance	Inline	FY25 EBITDA at □1,016 Cr vs. revised guidance of □1,000-1,050 Cr.	□
Earnings Quality	Moderate	PAT aided by lower tax (negative rate in Q4) but hit by high depreciation/finance costs from new assets.	□
Guidance Confidence	Neutral	Re-affirmed FY28 EBITDA target (□1,800-2,200 Cr), but relies on aggressive ~25% CAGR from here.	□
Management Credibility	Improving	Delivered on the "volume-led" recovery promise (+17% for FY25); debt has officially "peaked."	□
Business Quality Signal	Stable	Moat in Ethylation/Nitrotoluene chains remains intact; Energy (MMA) is volatile but gaining US/EU traction.	□
Key Q&A Exchange	Q4 on US Tariffs	Mgmt gave a nuanced, non-generic breakdown of tariff impacts (winners in PDA, losers in MMA).	□
The Street's Primary Anxiety	Pricing Power	Analysts pressed on why volumes are surging while pricing remains "depressed" (China overcapacity).	□
Capital Cycle Stage	Consolidation	Capex tapering from □1,372 Cr (FY25) to ~□1,000 Cr (FY26); shifting to asset sweating.	□
Margin Trajectory	Stable/Low	EBITDA margins suppressed by freight and pricing; internal cost optimization is the only tailwind.	□
Pricing Power	Eroding	Direct competition from China in Agchem/Dyes keeps realisations at "uncomfortable" levels.	□
FCF Conversion	Weak	Positive OCF expected in FY26 as working capital (Aniline inventory) unlocks.	□
Competitive Moat	Stable	Large-scale integration in Benzene/Toluene value chains remains the core competitive advantage.	□
Balance Sheet Strength	Adequate	Net Debt peaked at ~□3,500 Cr; Net Debt/EBITDA ~3.4x—needs to drop to 2.5x by FY28.	□
Working Capital	Deteriorating	Payable days doubled due to longer credit on Aniline; provides a temporary cash buffer.	□
Mgmt Guidance Record	Mixed	After the Q2 FY25 guidance cut, the current management team is meeting the "new" lowered bar.	□
Key Vulnerability	China Dumping	Risk of Chinese Agchem intermediates being dumped in non-US markets due to US tariffs.	□
Management Tone	Cautiously Confident	CEO Suyog Kotecha focused on "market development" and "cost agility" over macro hope.	□

Sentiment: □Neutral

Key Takeaways * **Positives:** Volume growth is the definitive engine, with FY25 seeing a 17% increase. Management successfully commissioned the Nitrotoluene and Ethylation expansions, which are now in the ramp-up phase. The peak of the capex cycle (₹1,372 Cr) is behind them, and debt has likely plateaued at ₹3,500 Cr. New renewable energy PPAs will start contributing to cost savings from H2 FY26. * **Negatives:** Pricing remains structurally broken. Despite volume recovery, management admits that Chinese overcapacity keeps pricing at levels they "do not like." The Energy (MMA) segment introduces volatility linked to gasoline-naphtha spreads, and US tariffs on MMA (not exempt) add a cost layer for end-customers. * **Street Concern:** Analysts are fixated on the disconnect between volume and value. Management's response: they are "market making" in MMA and focusing on internal cost levers (Back Pressure Turbines, Solar) because they cannot predict when China will stop dumping. * **Watchpoint:** Monitor the "Aniline Payable" lever; a reduction in credit terms could spike net debt despite management’s claim that debt has peaked.

---

2. BUSINESS PERFORMANCE

2A. KEY METRICS *DATA SOURCE: PPT figures used as primary source. Concall used for commentary and missing data points.*

Metric	Current Qtr (Q4FY25)	YoY Change	QoQ Change	Trend	Mgmt Commentary
Volume Growth (%)	+17% (FY25)	↑	↑	↑	Driven by 14% non-energy and 21% energy growth in Q4.
Realization/MT (₹)	Not in document	↓	→	↓	Pricing remains "under pressure" due to China supply-demand imbalance.
Utilization (%)	~70-75%	↑	↑	↑	NCB high; PDA/NT/Ethylation in ramp-up phase.
Gross Margin (%)	~42%	↓	→	↓	Suppressed by Chinese competition and MMA spread adjustments.
EBITDA (₹Cr)	₹266 Cr	↑ 14.7%	↑ 12.7%	↑	FY25 EBITDA at ₹1,016 Cr (vs ₹989 Cr in FY24).
EBITDA Margin %	12.0%	↑ 10 bps	↑ 40 bps	↑	Improvement led by operating leverage on higher volumes.
Revenue (₹Cr)	₹2,214 Cr	↑ 25.0%	↑ 8.8%	↑	FY25 Revenue hit ₹8,046 Cr (+15% YoY).
PAT (₹Cr)	₹96 Cr	↑ 3.2%	↑ 108.7%	↑	Q3 was hit by FX loss; Q4 saw tax reversals/low rate.
ROCE (%)	< 10%	↓	→	↓	Multi-year target of >15% remains the anchor for FY28.
Cash Flow (OCF)	Not in document	↓	→	↓	CFO hit by inventory; improvement expected in FY26.
Net Debt (₹Cr)	~₹3,500 Cr	↑	→	→	Mgmt claims debt has peaked; reduction target ₹200-300 Cr in FY26.
Working Capital (Days)	~75 Days	→	↑	↓	Payables jumped due to Aniline credit; Gross WC at 70-80 days.
Exports (₹Cr)	₹1,240 Cr	↑	↑	↑	55% of Q4 revenue; freight costs spiked other expenses.

2B. SEGMENT BREAKDOWN

Segment	Rev Share	YoY Volume	Margin	Trend	vs Company Avg	Key Development
Energy & Additives	~37%	↑ 21% (QoQ)	Volatile	□	Above Avg	MMA success in US/EU; freight costs an issue.
Agrochemicals	~19%	Recovering	Pressed	↓	Below Avg	Inventory normal; Chinese dumping risk remains high.
Dyes & Pigments	~12%	↑ Strong	Improving	↑	Above Avg	Domestic market share gain in PNCB/ PAP downstream.
Polymers	~13%	↑ Robust	Improving	↑	Above Avg	92% Export; PDA exports to USA showing "good traction."
Pharma	~9%	↑ Steady	Stable	→	Inline	Chlorotoluene ramp-up to open new Pharma opportunities.

3. MANAGEMENT OUTLOOK & EXECUTION TRACKER

Dimension	Category	Management Target / Claim	Required Run-Rate	Historical Delivery	Risk Flag
Guidance	FY25 EBITDA	□1,000 - □1,050 Cr	**Met** (□1,016 Cr)	Delivered on revised	Low
Guidance	FY28 EBITDA	□1,800 - □2,200 Cr	Needs ~23% EBITDA CAGR	New target	High
Guidance	FY26 Capex	□950 - □1,000 Cr	~□240 Cr/quarter	FY25 was □1,372 Cr	Medium
Guidance	FY28 ROCE	> 15%	Needs ~500-600bps expansion	Currently ~9-10%	High
Strategy	Debt/ EBITDA	< 2.5x by FY28	EBITDA must double	Currently ~3.4x	Medium
Strategy	Cost Savings	□150 - □200 Cr	Yield & Power initiatives	Ongoing; BPT commissioned	Low
Macro	US Tariffs	"Mixed Impact"	Mixed exposure	Real-time event	Medium

4. ANALYST Q&A

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
1	4.0	Kumar Saumya (Ambit)	Volume Growth	Business Overview	"Indications on YoY volume growth in FY25 and Q4?"	Management confirmed Q4 non-energy grew 14%, energy 21%, and total FY25 volume growth was 17%. Investment implication: Demand recovery is structural, but top-line growth is lagging volume due to pricing deflation.	None	5.0	Clear and quantified
2	4.5	Aditya Khetan (SMIFS)	Agchem Pricing	Business Overview	"Why are prices still weak if destocking ended 10 months ago?"	Management cited a genuine demand-supply imbalance from China overcapacity that serves incremental growth at marginal pricing. Investment implication: Agchem margins will remain bottom-of-cycle until global capacity utilization rebalances.	None	4.0	Directional evidence
3	4.0	Vivek Rajamani (MS)	MMA Strategy	Business Overview	"MMA customer base expansion impact on pricing?"	Management is focused on market development in US/Europe to diversify from the Middle East, with pricing linked to aniline/ gasoline economics. Investment implication:	None	3.0	Vague but consistent

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
						MMA is a "market-making" venture where scale precedes margin stability.			
4	5.0	Abhijit Akella (Kotak)	US Tariffs	Macro	"What are the implications of US tariff developments?"	Management gave a 3-tier breakdown: positive for MPD (China competition), mixed for Agchem (dumping risk), and negative for MMA (increased cost to customer). Investment implication: AIL is not a simple "China+1" beneficiary; the portfolio has significant second-order dumping risks.	None	5.0	Specific and nuanced
5	4.5	Arun Prasath (Spark)	Crude & MMA	Financials	"Impact of current crude prices on MMA spreads?"	Management explained that while crude/ raw materials are correcting, the gasoline-naphtha spread remains the key viability driver for customers. Investment implication: AIL's energy segment earnings remain hostage to global refining spreads they cannot control.	Spread forecast	3.0	Macro uncertainty
6	4.0			Financials			None	4.0	

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
		Harsh Shah (HSBC)	Balance Sheet		"Why did payable days double while debtor days reduced?"	Management attributed the jump to longer credit terms on imported aniline used for higher MMA volumes. Investment implication: The current debt stability is partially "funded" by vendors; any normalization here could stress cash flows.			Specific reason
7	4.5	Archit Joshi (Nuvama)	Utilization	Business Overview	"Visibility on PDA, NT, and Ethylation volume growth for FY26?"	Management expects PDA to see an uptick from US demand, NCB from Pharma customer expansions, and NT/ Ethylation to ramp up after being proven in Q4. Investment implication: FY26 growth is almost entirely dependent on "asset sweating" rather than new greenfield commissioning.	None	4.0	Specific timeline
8	4.0	Surya Patra (Phillip)	Exports	Financials	"What was the export number for the quarter?"	The CFO confirmed exports were □1,240 Cr (55% of revenue), up from ~48-50% historically. Investment implication: Higher export	None	5.0	Specific and quantified

Q#	Relevance	Analyst	Theme Cluster	Category	Underlying Concern	Management Response & Investment Implication	Evaded	Credibility	Verdict
						share is driving up freight costs, which explains why "Other Expenses" are outstripping sales growth.			
9	3.0	Siddharth Gadekar (Equitas)	Taxation	Financials	"How should we think about the tax rate for FY26?"	Management expects a mid-single-digit tax rate for FY26 as high depreciation from the heavy capex cycle continues. Investment implication: Lower tax provides a PAT cushion while EBITDA/ Interest coverage remains tight.	None	4.0	Directional
10	3.5	Jay Bharat Trivedi (Incred)	Capex Breakdown	Capex and Allocation	"Maintenance vs new chemistry split in the ₹1,000 Cr capex?"	Maintenance/ existing product capex is ₹150-200 Cr, with the remainder (~₹800 Cr) dedicated to new Zone 4 initiatives. Investment implication: Growth capex remains high at 80% of total spend, keeping the balance sheet in a high-intensity phase.	None	4.5	Clear breakdown

PATTERN FLAGS & SENTIMENT * **The China Dumping Anxiety:** Analysts repeatedly questioned why volume recovery isn't translating to pricing power. Management's posture was defensive but realistic, admitting they are price-takers in the current global glut. This remains a live risk—if China's domestic demand doesn't recover, AIL's volume growth will be "profitless" growth. * **Tariff Complexity:** Unlike typical "China+1" stories, management was very careful not to overpromise on US tariffs. They highlighted that while some products win, the "second and third-order impacts" (like China dumping surplus into India/EM) are a major unknown. * **The Aniline "Float":** A subtle but critical friction point was the jump in payables. Management used this to keep net debt stable, but analysts were skeptical of its sustainability.

Analyst Sentiment Verdict: Analysts were **skeptically encouraged**. They were satisfied that management hit the FY25 EBITDA floor but remained frustrated by the lack of pricing visibility. The CEO's detailed, molecule-level explanations on tariffs earned credibility, but the unhedged debt and dependence on Aniline credit terms remain significant valuation overhangs.

GUIDANCE GAPS REVEALED IN Q&A | Topic | Opening Claim | Q&A Revelation | Gap / Walk-back | Risk to Thesis | | :--- | :--- | :--- | :--- | :--- | | **Agchem Recovery** | Volumes are picking up. | Pricing remains "under pressure" due to China. | Recovery is volume-only, not value. | Medium | | **MMA (Energy)** | Growth is diversifying. | US Tariffs will add cost/compromise viability. | Tariff-led headwinds for new markets. | Medium | | **Net Debt** | Peaked at ₹3,500 Cr. | Jump in payables (₹600 Cr) helped maintain this. | Debt "plateau" is working-capital dependent. | High |

---

5. WHAT CHANGED vs PRIOR QUARTER

What Changed	Prior Quarter (Q3 FY25)	This Quarter (Q4 FY25)	Direction
EBITDA Run-rate	₹236 Cr (Q3)	₹266 Cr (Q4)	↑ Improving
Volume Growth	14% (Non-energy)	17% (Overall FY25)	↑ Improving
Capex Intensity	Peak (₹1,300-1,500 Cr range)	FY26 Guided at ~₹1,000 Cr	↑ FCF Positive Visibility
Export Mix	~50% of Revenue	55% of Revenue	↑ Improving
Working Capital	Stable	Payables doubled (Aniline credit)	↓ Lower Quality WC
Macro Outlook	"Wait and watch" on demand	Tariff-led "mixed" impact confirmed	□Increasing Complexity
Debt Trajectory	Peak pending	Peak confirmed at ~₹3,500 Cr	↑ Balance Sheet Stability
Tone	Recovery focus	Market development & Execution	↑ Strategic Clarity

Note on Thesis: The long-term thesis that AIL is the primary beneficiary of "China+1" in specialty chemicals is being tested by the reality of "China Dumping Everywhere Else." Investors should focus on the **FY26 Volume Ramp-up** of the Nitrotoluene and Ethylation plants; if these don't hit 80% utilization by H2 FY26, the ₹1,800-2,200 Cr FY28 target becomes mathematically improbable.